Клиническая эффективность препаратов на основе пробиотических штаммов Saccharomyces boulardii

Вход
Регистрация
Помощь

Выбрать БД

Журналы и статьиСоздатель/АффиляцияЭнциклопедия MeSH

Простой поискРасширенный поискИстория поисков

Главная / Результаты поиска

СтатьяМЕД СОВЕТ. 2020; № 5: 104–112. DOI:10.21518/2079-701X-2020-5-104-112

Клиническая эффективность препаратов на основе пробиотических штаммов Saccharomyces boulardii

Дроздов В.Н.^[1]

Арефьев К.И.^[1]

Сереброва С.Ю.^[1,2]

Ших Е.В.^[1]

^[1]Первый Московский государственный медицинский университет им. И. М. Сеченова (Сеченовский университет)

^[2]Научный центр экспертизы средств медицинского применения (Москва)

Микрофлора кишечника в свете интегральной совокупности знаний о ее значимости для организма человека рассматривается в настоящее время как дополнительный «виртуальный» орган, продуцирующий множество биологически активных соединений, влияющих на различные свойства и функции макроорганизма: ферментацию неперевариваемых пищевых полисахаридов, поддержание оптимальных значений внутрипросветного рН и «кишечного барьера», активность иммунной системы, витаминный статус, энергетический гомеостаз, ангиогенез. Saccharomycesboulardii не является представителем естественной микрофлоры кишечника человека, но, применяемый как пробиотик, взаимодействует с ней, восстанавливая баланс короткоцепочечных жирных кислот, снижая уровни бактериальных токсинов, действуя как суррогатная нормальная микрофлора до момента восстановления и замещения естественными ее представителями. S. boulardii обладает иммуностимулирующей и противовоспалительной активностью. Результаты клинических исследований продемонстрировали эффективность применения S. boulardii при коррекции патологических состояний, ассоциированных с Helicobacterpylori, Clostridiumdifficile, Candidaalbicans, Salmonellatyphimurum, Yersiniaenterocolitium, простейшими рода Entamoeba, а также при лечении синдрома раздраженного кишечника и антибиотик-ассоциированной диареи. Эффективность лекарственного препарата, содержащего S. boulardii, продемонстрирована в статье результатами клинических исследований и клиническим примером. Этот лекарственный препарат зарекомендовал себя как высокоэффективное и безопасное пробиотическое средство, позволяющее предотвращать и лечить ряд заболеваний желудочно-кишечного тракта, обладающее физиологически-оптимизированным фармакодинамическим эффектом, имитирующим защитные свойства нормальной микрофлоры кишечника человека. При использовании лекарственного препарата, содержащего S. boulardii, как у взрослых, так и у детей не наблюдаются серьезные побочные эффекты, что расширяет возможности его безопасного применения в клинической практике.

Vyas U., Ranganathan N. Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterol Res Pract. 2012;2012:872716. doi: 10.1155/2012/872716..
DOI: 10.1155/2012/872716

De Palma G., Lynch M.D., Lu J., Dang V.T., Deng Y, Jury J. et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med. 2017;9:eaaf6397. doi: 10.1126/scitranslmed.aaf6397..
DOI: 10.1126/scitranslmed.aaf6397

Wiley N.C., Dinan T.G., Ross R.P., Stanton C., Clarke G., Cryan J.F. The microbiota-gut-brain axis as a key regulator of neural function and the stress response: Implications for human and animal health. J Anim Sci. 2017;95(7):3225-3246. doi: 10.2527/jas.2016.1256..
DOI: 10.2527/jas.2016.1256

Bull MJ., Plummer N.T. Part 1: The human gut microbiome in health and disease. Integr Med (Encinitas). 2014;13(6):17-22. pmid:26770121. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26770121.https://www.ncbi.nlm.nih.gov/pubmed/26770121

Rath C.M., Dorrestein P.C. The bacterial chemical repertoire mediates metabolic exchange within gut microbiomes. Curr Opin Microbiol. 2012;15(2):147-154. doi: 10.1016/j.mib.2011.12.009..
DOI: 10.1016/j.mib.2011.12.009

Dutton RJ., Turnbaugh PJ. Taking a metagenomic view of human nutrition. Curr Opin Clin Nutr Metab Care. 2012;15(5):448-454. doi: 10,1097/MCO.0b013e3283561133..
DOI: 10,1097/MCO.0b013e3283561133

Dominguez-Bello M.G., Blaser MJ. Do you have a probiotic in your future? Microbes Infect. 2008;10(9):1072-1076. doi: 10.1016/j.micinf.2008.07.036..
DOI: 10.1016/j.micinf.2008.07.036

Wong J.M., de Souza R., Kendall C.W., Emam A., Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40(3):235-243. doi: 10.1097/00004836-200603000-00015..
DOI: 10.1097/00004836-200603000-00015

Macfarlane G.T., Macfarlane S. Bacteria, colonic fermentation, and gastrointestinal health. J AOAC Int. 2012;95(1):50-60. doi: 10.5740/jaoacint.sge_macfarlane..
DOI: 10.5740/jaoacint.sge_macfarlane

Long S.L., Gahan C.G.M., Joyce S.A. Interactions between gut bacteria and bile in health and disease. Mol Aspects Med. 2017;56:54-65. doi: 10.1016/j.mam.2017.06.002..
DOI: 10.1016/j.mam.2017.06.002

Tang W.H., Wang Z., Levison B.S., Koeth R.A., Britt E.B., Fu X. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575-1584. doi: 10.1056/NEJMoa1109400..
DOI: 10.1056/NEJMoa1109400

de Mello V.D., Paananen J., Lindstrom J., Lankinen M., Shi L., Kuusisto J. et al. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study. Sci Rep. 2017;7:46337. doi: 10.1038/srep46337..
DOI: 10.1038/srep46337

Chyan YJ., Poeggeler B., Omar R.A., Chain D., Frangione B., Ghiso J., Pappolla M.A. Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatoninrelated indole structure, indole-3-propionic acid. J Biol Chem. 1999;274:21937-21942. doi: 10.1074/jbc.274.31.21937..
DOI: 10.1074/jbc.274.31.21937

Martens J.H., Barg H., Warren MJ., Jahn D. Microbial production of vitamin B12. Appl Microbiol Biotechnol. 2002;58:275-285. doi: 10.1007/s00253-001-0902-7..
DOI: 10.1007/s00253-001-0902-7

LeBlanc J.G., Milani C., de Giori G.S., Sesma F., van Sinderen D., Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013;24(2):160-168. doi: 10.1016/j.copbio.2012.08.005..
DOI: 10.1016/j.copbio.2012.08.005

Hill MJ. Intestinal flora and endogenous vitamin synthesis. EurJ Cancer Prev. 1997;6:S43-S45. doi: 10.1097/00008469-199703001-00009..
DOI: 10.1097/00008469-199703001-00009

Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S. et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328:228-231. doi: 10.1126/science.1179721..
DOI: 10.1126/science.1179721

Round J.L., Lee S.M., Li J., Tran G., Jabri B., Chatila T.A., Mazmanian S.K. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. 2011;332:974-977. doi: 10.1126/sci-ence.1206095..
DOI: 10.1126/sci-ence.1206095

Carvalho F.A., Koren O., Goodrich J.K., Johansson M.E., Nalbantoglu I., Aitken J.D. et al. Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe. 2012;12(2):139-152. doi: 10.1016/j.chom.2012.07.004..
DOI: 10.1016/j.chom.2012.07.004

Bien J., Palagani V., Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Ther Adv Gastroenterol. 2013;6(1):53-68. doi: 10.1177/1756283X12454590..
DOI: 10.1177/1756283X12454590

Knights D., Lassen K., Xavier R. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut. 2013;62(10):1505-1510. doi: 10.1136/gutjnl-2012-303954..
DOI: 10.1136/gutjnl-2012-303954

Walker A.W., Sanderson J., Chercher C., Parkres G.C., Hudspith B.N., Rayment N. et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and diferences between infamed and non-infamed regions of the intestine in infammatory bowel disease. BMC Microbiol. 2011;11:7. doi: 10,1186/1471-2180-11-7..
DOI: 10,1186/1471-2180-11-7

Buttó L.F., Schaubeck M., Haller D. Mechanisms of microbe-host interaction in Crohn's disease: dysbiosis vs. pathobiont selection. Front Immunol. 2015;6:555. doi: 10.3389/fimmu.2015.00555..
DOI: 10.3389/fimmu.2015.00555

Keeney K.M., Yurist-Doutsch S., Arrieta M.C., Finlay B.B. Effects of antibiotics on human microbiota and subsequent disease. Annu Rev Microbiol. 2014;68:217-235. doi: 10.1146/annurev-micro-091313-103456..
DOI: 10.1146/annurev-micro-091313-103456

Vangay P., Ward T., Gerber J.S., Knights D. Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe. 2015;17(5):553-564. doi: 10.1016/j.chom.2015.04.006..
DOI: 10.1016/j.chom.2015.04.006

Collins S.M. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol. 2014;11(8):497-505. doi: 10.1038/nrgastro.2014.40..
DOI: 10.1038/nrgastro.2014.40

Day A.S., Lopez R.N. Exclusive enteral nutrition in children with Crohn's disease. World J Gastroenterol. 2015;21(22):6809-6816. doi: 10.3748/wjg.v21.i22.6809..
DOI: 10.3748/wjg.v21.i22.6809

Sheikh Sajjadieh M.R., Kuznetsova L.V., Bojenko V.B. Dysbiosis in Ukrainian children with irritable bowel syndrome affected by natural radiation. Iran J Pediatr. 2012;22(3):364-368. Available at: https://www.researchgate.net/publication/235522481_Dysbiosis_in_Ukrainian_Children_with_Irritable_Bowel_Syndrome_Affected_by_Natural_Radiation.https://www.researchgate.net/publication/235522481_Dysbiosis_in_Ukrainian_Children_with_Irritable_Bowel_Syndrome_Affected_by_Natural_Radiation

Gerard P. Gut microbiota and obesity. Cell Mol Life Sci. 2016;73(1):147-162. doi: 10.1007/s00018-015-2061-5..
DOI: 10.1007/s00018-015-2061-5

Knip M., Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol. 2016;12(3):154-167. doi: 10.1038/nrendo.2015.218..
DOI: 10.1038/nrendo.2015.218

Knip M., Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol. 2016;12(3):154-167. doi: 10.1038/nrendo.2015.218..
DOI: 10.1007/s00018-015-2061-5

Tremlett H., Bauer K.C., Appel-Cresswell S., Finlay B.B., Waubant E. The gut microbiome in human neurological disease: a review. Ann Neurol. 2017;81(3):369-382. doi: 10.1002/ana.24901..
DOI: 10.1002/ana.24901

Neu J., Walker W.A. Necrotizing enterocolitis. N Engl J Med. 2011;364(3):255-264. doi: 10,1056/NEJMra1005408..
DOI: 10,1056/NEJMra1005408

Neu J., Walker W.A. Necrotizing enterocolitis. N Engl J Med. 2011;364(3):255-264. doi: 10,1056/NEJMra1005408..
DOI: 10.1038/nrendo.2015.218

Schwabe R.F., Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800-812. doi: 10,1038/nrc3610..
DOI: 10,1038/nrc3610

Schwabe R.F., Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800-812. doi: 10,1038/nrc3610..
DOI: 10.1002/ana.24901

Seekatz A.M., Young V.B. Clostridium difficile and the microbiota. J Clin Invest. 2014;124(10):4182-4189. doi: 10.1172/JCI72336..
DOI: 10.1172/JCI72336

Seekatz A.M., Young V.B. Clostridium difficile and the microbiota. J Clin Invest. 2014;124(10):4182-4189. doi: 10.1172/JCI72336..
DOI: 10.1002/ana.24901

Lyra A., Rinttila T., Nikkila J., Krogius-Kurikka L., Kajander K., Malinen E. et al. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol. 2009;15(47):5936-5945. doi: 10.3748/wjg.15.5936..
DOI: 10.3748/wjg.15.5936

McFarland L.V. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202-2222. doi: 10.3748/wjg.v16.i18.2202..
DOI: 10.3748/wjg.v16.i18.2202

Czerucka D., Piche T., Rampal P. Review article: yeast as probiotics -Saccharomyces boulardii. Aliment Pharmacol Ther. 2007;26(6):767-778. doi: 10.1111/j.1365-2036.2007.03442.x..
DOI: 10.1111/j.1365-2036.2007.03442.x

Elmer G.W., McFarland L.V., McFarland M., Russo E. (eds.) The power of probiotics: improving your health with beneficial microbes. Binghamton, NY: Haworth Press; 2007. 256 p. Available at: https://content.taylorfrancis.com/books/download?dac=C2008-0-34744-1&isbn=9781317824961&for mat=googlePreviewPdf..
DOI: 10,1038/nrc3610https://content.taylorfrancis.com/books/download?dac=C2008-0-34744-1&isbn=9781317824961&for

Pothoulakis C. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther. 2009;30(8):826-833. doi: 10.1111/j.1365-2036.2009.04102.x..
DOI: 10.1111/j.1365-2036.2009.04102.x

Ng S.C., Hart A.L., Kamm M.A., Stagg AJ., Knight S.C. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis. 2009;15(2):300-310. doi: 10,1002/ibd.20602..
DOI: 10,1002/ibd.20602

Ng S.C., Hart A.L., Kamm M.A., Stagg AJ., Knight S.C. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis. 2009;15(2):300-310. doi: 10,1002/ibd.20602..
DOI: 10.1172/JCI72336

Pothoulakis C., Kelly C.P., Joshi M.A., Gao N., O'Keane CJ., Castagliuolo I., Lamont J.T. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993;104:1108-1115. doi: 10.1016/0016-5085(93)90280-p..
DOI: 10.1016/0016-5085(93)90280-p

Brandao R.L., Castro I.M., Bambirra EA., Amaral S.C., Fietto L.G., Tropia MJ. et al. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol. 1998;64(2):564-568. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9464394..
DOI: 10.3748/wjg.15.5936https://www.ncbi.nlm.nih.gov/pubmed/9464394

Castagliuolo I., LaMont J.T., Nikulasson S.T., Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun. 1996;64(12):5225-5232. Available at: https://www. ncbi.nlm.nih.gov/pubmed/8945570..
DOI: 10.3748/wjg.v16.i18.2202https://www

Buts J.P., Dekeyser N., Stilmant C., Delem E., Smets F., Sokal E. Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr Res. 2006;60:24-29. doi: 10.1203/01.pdr.0000220322.31940.29..
DOI: 10.1203/01.pdr.0000220322.31940.29

Vidon N., Huchet B., Rambaud J.C. Influence of S. boulardii on jejunal secretions in rats induced by cholera toxin. Gastroenterol Clin Biol. 1986;10(1):13-16. (In French) Available at: https://www.ncbi.nlm.nih.gov/pubmed/3956910..
DOI: 10.1111/j.1365-2036.2007.03442.xhttps://www.ncbi.nlm.nih.gov/pubmed/3956910

Czerucka D., Rampal P. Effect of Saccharomyces boulardii on cAMP- and Ca2+-dependent Cl-secretion in T84 cells. Dig Dis Sci. 1999;44:2359-2368. Available at: https://link.springer.com/article/10.1023/A:1026689628136..
DOI: 10.1111/j.1365-2036.2007.03442.xhttps://link.springer.com/article/10.1023/A:1026689628136

Zbinden R. Inhibition of Saccharomyces boulardii (nom. inval.) on cell invasion of Salmonella typhimurium and Yersinia enterocolitica. Micro Ecol Health Dis. 1999;11(3):158-162. doi: 10.1080/089106099435736..
DOI: 10.1080/089106099435736https://content.taylorfrancis.com/books/download?dac=C2008-0-34744-1&isbn=9781317824961&for

Altwegg M., Schnack J., Zbinden R. influence of Saccharomyces bouLardii on Aeromonas hemolysin. Med Microbiol Lett. 1995;4:417-425.https://content.taylorfrancis.com/books/download?dac=C2008-0-34744-1&isbn=9781317824961&for

Dahan S., Dalmasso G., imbert V., Peyron J.F., RampaL P., Czerucka D. Saccharomyces bouLardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun. 2003;71(2):766-773. Available at: https://iai.asm.org/content/71/2/766..
DOI: 10.1111/j.1365-2036.2009.04102.xhttps://iai.asm.org/content/71/2/766

Wu X., Vallance B.A., Boyer L., Bergstrom K.S., Walker J., Madsen K. et al. Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):G295-G306. doi: 10.1152/ajpgi.00173.2007..
DOI: 10.1152/ajpgi.00173.2007

Garcia Vilela E., De Abreu Ferrari M., Da Gama Torres H.O, Guerra Pinto A., Carneiro Aguirre A.C., Paiva Martins F. et al. influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol. 2008;43(7):842-848. doi: 10.1080/00365520801943354..
DOI: 10.1080/00365520801943354

Dethlefsen L., Huse S., Sogin M.L., Relman D.A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoSBiol. 2008;6:e280. doi: 10.1371/journal.pbio.0060280..
DOI: 10.1371/journal.pbio.0060280

Girard-pipau F., Pompei A., Nano J.L., Boquet X., Rampal P. intestinal microflora, short chain and cellular fatty acids, influence of a probiotic S. boulardii. Microb Ecology Health Dis. 2002;14(4):220-228. doi: 10.1080/08910600310002109..
DOI: 10.1080/08910600310002109

Swidsinski A., Loening-Baucke V., Verstraelen H., Osowska S., Doerffel Y Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology. 2008;135(2):568-579. doi: 10.1053/j.gastro.2008.04.017..
DOI: 10.1053/j.gastro.2008.04.017

Barc M.C., Charrin-Sarnel C., Rochet V., Bourlioux F., Sandrę C., Boureau H. et al. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: influence of Saccharomyces boulardii. Anaerobe. 2008;14(4):229-233. doi: 10.1016/j.anaerobe.2008.04.003..
DOI: 10.1016/j.anaerobe.2008.04.003https://www.ncbi.nlm.nih.gov/pubmed/9464394

Breves G., Walter C., Burmester M., Schroder B. in vitro studies on the effects of Saccharomyces boulardii and Bacillus cereus var. toyoi on nutrient transport in pig jejunum. J Anim Physiol. 2000:84(1-2):9-20. doi: 10.1046/j.1439-0396.2000.00277.x..
DOI: 10.1046/j.1439-0396.2000.00277.xhttps://www.ncbi.nlm.nih.gov/pubmed/9464394

Schneider S.M., Girard-Pipau F., Filippi J., Hebuterne X., Moyse D., Hinojosa G.C. et al. Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J Gastroenterol. 2005;11(39):6165-6169. doi: 10.3748/tojg.v11.i39.6165..
DOI: 10.3748/tojg.v11.i39.6165https://www

Ozkan T.B., Sahin E., Erdemir G., Budak F. Effect of Saccharomyces boulardii in children with acute gastroenteritis and its relationship to the immune response. J Int Med Res. 2007;35(2):201-212. doi: 10.1177/147323000703500204..
DOI: 10.1177/147323000703500204https://www

Buts J.-P. Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. Dig Dis Sci. 2009;54:15-18. Available at: https://link.springer.com/article/10.1007/s10620-008-0322-y..
DOI: 10.1203/01.pdr.0000220322.31940.29https://link.springer.com/article/10.1007/s10620-008-0322-y

Martins F.S., Silva AA., Vieira A.T., Barbosa F.H., Arantes R.M., Teixeira M.M., Nicoli J.R. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch Microbiol. 2009;191:623-630. doi: 10.1007/s00203-009-0491-x..
DOI: 10.1007/s00203-009-0491-x

Pant N., Marcotte H., Brussow H., Svensson L., Hammarstrom L. Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies. BMC Microbiol. 2007;7:86. doi: 10.1186/1471-2180-7-86..
DOI: 10.1186/1471-2180-7-86https://www.ncbi.nlm.nih.gov/pubmed/3956910

Kyne L., Warny M., Oamar A., Kelly C.P Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189-193. doi: 10.1016/S0140-6736(00)03592-3..
DOI: 10.1016/S0140-6736(00)03592-3https://www.ncbi.nlm.nih.gov/pubmed/3956910

Chen X., Kokkotou E.G., Mustafa N., Bhaskar K.R., Sougioultzis S., O'Brien M. et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem. 2006;281:24449-24454. doi: 10.1074/jbc.M605200200..
DOI: 10.1074/jbc.M605200200https://link.springer.com/article/10.1023/A:1026689628136

Dalmasso G., Cottrez F., imbert V., Lagadec P, Peyron J.F., Rampal P et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology. 2006;131(6):1812-1825. doi: 10.1053/j.gastro.2006.10.001..
DOI: 10.1053/j.gastro.2006.10.001https://link.springer.com/article/10.1023/A:1026689628136

Tong J.L., Ran Z.H., Shen J., Zhang C.X., Xiao S.D. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155-168. doi: 10.1111/j.1365-2036.2006.03179.x..
DOI: 10.1111/j.1365-2036.2006.03179.x

Duman D.G., Bor S., Ozutemiz O., Sahin T., Oguz D., i§tan F. et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication. EurJ Gastroenterol Hepatol. 2005;17(12):1357-1361. doi: 10.1097/00042737-200512000-00015..
DOI: 10.1097/00042737-200512000-00015

Vandenplas Y., Brunser O., Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr. 2009;168:253-265. doi: 10.1007/s00431-008-0879-7..
DOI: 10.1007/s00431-008-0879-7

Gotteland M., Poliak L., Cruchet S., Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr. 2005;94(12):1747-1751. doi: 10.1111/j.1651-2227.2005.tb01848.x..
DOI: 10.1111/j.1651-2227.2005.tb01848.x

Hochter W., Chase D., Hagenhoff G. Saccharomyces boulardii in acute adult diarrhea: efficacy and tolerability of treatment. Munch Med Wschr. 1990;132:188-192.https://iai.asm.org/content/71/2/766

Mansour-Ghanaei F., Dehbashi N., Yazdanparast K., Shafaghi A. Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World J Gastroenterol. 2003;9(8):1832-1833. doi: 10.3748/wjg.v9.i8.1832..
DOI: 10.3748/wjg.v9.i8.1832https://iai.asm.org/content/71/2/766

Htwe K., Yee K.S., Tin M., Vandenplas Y. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg. 2008;78(2):214-216. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18256417..
DOI: 10.1152/ajpgi.00173.2007https://www.ncbi.nlm.nih.gov/pubmed/18256417

Billoo A.G., Memon M.A., Khaskheli S.A., Murtaza G., iqbal K., Saeed S.M. et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol. 2006;12(28):4557-4560. doi: 10.3748/wjg.v12.i28.4557..
DOI: 10.3748/wjg.v12.i28.4557

Kurugol Z., Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr. 2005;94(1):44-47. doi: 10.1111/j.1651-2227.2005.tb01786.x..
DOI: 10.1111/j.1651-2227.2005.tb01786.x

Villarruel G., Rubio D.M., Lopez F., Cintioni J., Gurevech R., Romero G., Vandenplas Y Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatr. 2007;96(4):538-541. doi: 10.1111/j.1651-2227.2007.00191.x..
DOI: 10.1111/j.1651-2227.2007.00191.x

Szajewska H., Skorka A., Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther. 2007;25(3):257-264. doi: 10.1111/j.1365-2036.2006.03202.x..
DOI: 10.1111/j.1365-2036.2006.03202.x

Szajewska H., Skorka A. Saccharomyces boulardii for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials. Aliment Pharmacol Ther. 2009;30(9):960-961. doi: 10.1111/j.1365-2036.2009.04113.x..
DOI: 10.1111/j.1365-2036.2009.04113.x

Леонтьева Н.И., Щербаков И.Т., Грачева Н.М., Хренников Б.Н., Соловьева А.И. Эффективность влияния пробиотического препарата «Энтерол» на процессы репарации разных отделов слизистой оболочки желудочно-кишечного тракта. Экспериментальная и клиническая гастроэнтерология. 2015;(5). Режим доступа: https//cyberleninka.ru/ article/n/effektivnost-vliyaniya-probioticheskogo-preparata-enterol-na-protsessy-reparatsii-raznyh-otdelov-slizistoy-obolochkizheludochno..
DOI: 10.1080/08910600310002109https//cyberleninka.ru/

Guarino A., Albano F., Ashkenazi S., Gendrel D., Hoekstra J.H., Shamir R. et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr. 2008;46:S81-S122. doi: 10.1097/MPG.0b013e31816f7b16..
DOI: 10.1097/MPG.0b013e31816f7b16

McFarland L.V., Surawicz C.M., Greenberg R.N., Fekety R., Elmer G.W., Moyer K.A. et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271(24):1913-1918. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8201735..
DOI: 10.1053/j.gastro.2008.04.017https://www.ncbi.nlm.nih.gov/pubmed/8201735

Surawicz C.M., McFarland L.V., Greenberg R.N., Rubin M., Fekety R., Mulligan M.E. et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012-1017. doi: 10.1086/318130..
DOI: 10.1086/318130

McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97(7):1769-1775. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12135033..
DOI: 10.1016/j.anaerobe.2008.04.003https://www.ncbi.nlm.nih.gov/pubmed/12135033

McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101(4):812-822. Available at: https://www.ncbi. nlm.nih.gov/pubmed/16635227..
DOI: 10.1016/j.anaerobe.2008.04.003https://www.ncbi

Parkes G.C., Brostoff J., Whelan K., Sanderson J.D. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol. 2008;103(6):1557-1567. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18513268..
DOI: 10.1046/j.1439-0396.2000.00277.xhttps://www.ncbi.nlm.nih.gov/pubmed/18513268

McFarland L.V., Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14(17):2650-2661. doi: 10.3748[%]2Fwjg.14.2650..
DOI: 10.3748[%]2Fwjg.14.2650

Choi C.H., Jo S.Y., Park HJ., Chang S.K., Byeon J.S., Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol. 2011;45(8):679-683. doi: 10.1097/MCG.0b013e318204593e..
DOI: 10.1097/MCG.0b013e318204593e

Bennani A. Randomized trial of Saccharomyces boulardii in the treatment of functional colon disorders. LObjectif Medical. 1990;73:56-61..
DOI: 10.3748/tojg.v11.i39.6165

Maupas J.L., Champemont P., Delforge M. Treatment of irritable bowel syndrome with Saccharomyces boulardii: a double-blind, placebocon-trolled study. Med Chir Dig. 1983;12:77-79..
DOI: 10.1177/147323000703500204

Guslandi M. Treatment of irritable bowel syndrome with Saccharomyces boulardii. J Clin Gastroenterol. 2011;45(8):740-741. doi: 10.1097/MCG.0b013e3182166c76..
DOI: 10.1097/MCG.0b013e3182166c76

Guslandi M. Treatment of irritable bowel syndrome with Saccharomyces boulardii. J Clin Gastroenterol. 2011;45(8):740-741. doi: 10.1097/MCG.0b013e3182166c76..
DOI: 10.1177/147323000703500204

Monteiro E., Fernandes J.P., Vieira M.R., Correia J.P, Caetano J.M., Ribeiro T. et al. Double blind clinical trial on the use of ultra-levure in the prophylaxis of antibiotic induced gastro-intestinal and mucocutaneous disorders. Acta Med Port. 1981;3(2):143-145. (In Portuguese) Available at: https://www.ncbi.nlm.nih.gov/pubmed/7032230.https://www.ncbi.nlm.nih.gov/pubmed/7032230

McFarland L.V., Surawicz C.M., Greenberg R.N., Elmer G.W., Moyer K.A., Melcher S.A. et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol. 1995;90(3):439-448. Available at: https://www.ncbi.nlm.nih.gov/pub-med/7872284.https://www.ncbi.nlm.nih.gov/pub-med/7872284

Can M., Beirbellioglu B.A., Avci I.Y., Beker C.M., Pahsa A. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit. 2006;12(4):PI19-PI22. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16572062..
DOI: 10.1007/s00203-009-0491-xhttps://www.ncbi.nlm.nih.gov/pubmed/16572062

Duman D.G., Bor S., Ozutemiz O., Sahin T., Oguz D., I§tan F. et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication. Eur J Gastroenterol Hepatol. 2005;17(12):1357-1361. doi: 10.1097/00042737-200512000-00015..
DOI: 10.1097/00042737-200512000-00015

Cremonini F., Di Caro S., Covino M., Armuzzi A., Gabrielli M., Santarelli L. et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002;97(11):2744-2749. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12425542..
DOI: 10.1186/1471-2180-7-86https://www.ncbi.nlm.nih.gov/pubmed/12425542

Cindoruk M., Erkan G., Karakan T., Dursun A., Unal S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled doubleblind study. Helicobacter. 2007;12(4):309-316. doi: 10.1111/j.1523-5378.2007.00516.x..
DOI: 10.1111/j.1523-5378.2007.00516.x

Kotowska M., Albrech P., Szajewska H. Saccharomyces boulardii in the prevention of antibioticassociated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21(5):583-590. doi: 10.1111/j.1365-2036.2005.02356.x..
DOI: 10.1111/j.1365-2036.2005.02356.x

Szajewska H., Mrukowicz J. Metaanalysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2005;22(5):365-372. doi: 10.1111/j.1365-2036.2005.02624.x..
DOI: 10.1111/j.1365-2036.2005.02624.x

Лузина Е.В. Антибиотикоассоциированная диарея. Сибирский медицинский журнал (Иркутск). 2009;(2):122-124. Режим доступа: https://cyberleninka.ru/article/n/antibiotikoassotsiirovannaya-diareya..
DOI: 10.1074/jbc.M605200200https://cyberleninka.ru/article/n/antibiotikoassotsiirovannaya-diareya

Бегайдарова Р.Х., Стариков Ю.Г., Алшынбекова Г.К., Дюсембаева А.Е., Девдариани Х.Г. Роль энтерола (saccharomyces boulardii) в профилактике и лечении антибиотикоассоциированной диареи у детей. Международный журнал прикладных и фундаментальных исследований. 2017;(11-1):40-44. Режим доступа: https://applied-research.ru/ru/article/view?id=11927..
DOI: 10.1074/jbc.M605200200https://applied-research.ru/ru/article/view?id=11927

Micklefield G. Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea. MMW Fortschr. Med. 2014;156(1):8-22. (In German) Available at: https://www.ncbi.nlm.nih.gov/pubmed/24930328..
DOI: 10.1053/j.gastro.2006.10.001https://www.ncbi.nlm.nih.gov/pubmed/24930328

Shan L.S., Hou P, Wang Z.-J., Liu F.-R., Chen N., Csu L-H. Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections. Benef. Microbes. 2013;4(4):329-334. doi: 10.3920/BM2013.0008..
DOI: 10.3920/BM2013.0008

Язык текста: Русский

ISSN: 2079-701X

Навигация
Аффилированные организации
Аннотация
Ключевые слова
Рубрики Mesh
Литература
Дополнительная информация

URI:4e432d4d4544534f5645542d41525449434c452d323032302d302d352d302d3130342d313132

Унифицированный идентификатор ресурса для цитирования: //medj.rucml.ru/journal/4e432d4d4544534f5645542d41525449434c452d323032302d302d352d302d3130342d313132/